Navigation Links
Guggenheim Securities Expands Healthcare Equity Research Team
Date:8/14/2012

NEW YORK, Aug. 14, 2012 /PRNewswire/ -- Guggenheim Partners, LLC ("Guggenheim"), a global diversified financial services firm, today announced two appointments to its Equity Research team. Louise Chen, Managing Director, will cover the specialty pharmaceutical sector, and Bret Holley, Managing Director, will cover the biotechnology sector. Based in New York, both analysts will report to Raymond Katz, Director of Equity Research for Guggenheim Partners.

"We are excited to have two seasoned and talented analysts join our team. Guggenheim's growing equity research practice is strongly positioned to offer investors and the marketplace timely and informed analysis of the healthcare industry as it undergoes unprecedented change," said Mr. Katz.

Ms. Chen joins Guggenheim from New York-based firm Auriga USA LLC, where she was a Managing Partner and Senior Analyst of Equity Research. At Auriga, Ms. Chen covered small-to-mid cap specialty pharmaceutical companies such as Teva Pharmaceutical Industries, Forest Laboratories and Warner Chilcott. Prior to Auriga, she spent several years at investment bank Canaccord Genuity, where she led the coverage of 14 leading specialty pharmaceutical companies. Earlier in her career, Ms. Chen worked as a Vice President of Equity Research at Morgan Stanley and as a business development executive at Dr. Reddy's Laboratories.

Mr. Holley joins Guggenheim with more than 15 years of experience in the biotechnology sector.  He was most recently a Managing Director and Senior Research Analyst at Oppenheimer & Co., formerly CIBC World Markets, where  he spent more than a decade leading the coverage of some of the world's largest biotechnology companies, including Amgen Inc., Celgene Corp., Gilead Sciences and ImmunoGen, Inc. Earlier in his career, Mr. Holley was a bioinformatics application architect at Ingenuity Systems where he developed biotechnology data software and worked with major biotech and pharmaceutical companies.

About Guggenheim Partners
Guggenheim Partners, LLC is a privately held global financial services firm with more than $160 billion in assets under management. The firm provides asset management, investment banking and capital markets services, insurance, institutional finance and investment advisory solutions to institutions, governments and agencies, corporations, investment advisors, family offices and individuals. Guggenheim Partners is headquartered in New York and Chicago and serves clients around the world from more than 25 offices in nine countries. For more information about Guggenheim Partners, visit www.guggenheimpartners.com.

Contacts:
Torie von Alt
Guggenheim Partners
+1 212 378 6216
Torie.vonalt@guggenheimpartners.com

Or

Tripp Kyle / Mary Zimmerman
Brunswick Group
+1 212 333 3810
guggenheim@brunswickgroup.com


'/>"/>
SOURCE Guggenheim Partners, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hill-Rom to Participate in the Deutsche Bank Securities Health Care Conference
2. Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
3. Omeros to Present at Deutsche Bank Securities Health Care Conference
4. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
5. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
6. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
7. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
8. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
9. ViroPharma To Participate In The JMP Securities Healthcare Conference
10. Isis Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
11. Uroplasty To Present At The JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):